Search
Research
Childhood and parental diagnostic radiological procedures and risk of childhood brain tumorsWe found no evidence of positive associations between risk of childhood brain tumours overall and childhood or parental pre-pregnancy radiological procedures.
Research
The Childhood Leukemia International ConsortiumThe Childhood Leukemia International Consortium (CLIC) was established in 2007 to promote investigations of rarer exposures, gene-environment interactions...
Research
Parental alcohol consumption and risk of childhood acute lymphoblastic leukemia and brain tumorsChildhood acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and brain tumors (CBTs) are the leading cause of cancer death in...
News & Events
Finding new treatments for rare brain cancers in infantsThe WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.
People
Professor Nick GottardoHead of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids Research Institute Australia
News & Events
Funding boost to melanoma researchA The Kids Research Institute Australia researcher will investigate new ways to harness the body’s own immune system to fight melanoma, thanks to Cancer Council WA funding.
News & Events
Adventurers deliver on a promise to help kids with cancerA state of the art 3D molecular imager that will help researchers monitor how brain tumours grow has been delivered to the Telethon Institute.
Research
Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumorsCitation: Sek K, Chen AXY, Cole T, Armitage JD, Tong J, ……… Waithman J, Parish IA, et al. Tumor site-directed A1R expression enhances CAR T cell
Research
Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumoursT cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity.
Research
Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemiaThere are few options for patients with relapse/refractory B-cell acute lymphoblastic leukemia, thus this is a major area of unmet medical need. Here, we reveal that inclusion of a poison exon in RBM39, which could be induced both by CDK9 or CDK9 independent CMGC (cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases) kinase inhibition, is recognized by the nonsense-mediated mRNA decay pathway for degradation.